Department of Microbiology and Immunology,
Tohoku University School of Dentistry, Aoba-ku, Sendai,
980-8575,1 Department of Microbiology
and Immunology, Kagoshima University Dental School, Kagoshima,
890-8544,2 Department of Biochemistry
and Cell Biology, National Institute of Infectious Diseases,
Shinjuku-ku, Tokyo 152-8640,3
Laboratory of Immunopharmacology of Microbial Products, Tokyo
University of Pharmacy and Life Science, Hachioji, Tokyo
192-0392,4 Department of Immunology,
Saga Medical School, Saga 849-8501,5 and
Department of Chemistry, Graduate School of Science, Osaka
University, Toyonaka 560-0043,6 Japan
Received 25 September 2000/Returned for modification 19 October
2000/Accepted 28 December 2000
Teichuronic acid (TUA), a component of the cell walls of the
gram-positive organism Micrococcus luteus (formerly
Micrococcus lysodeikticus), induced inflammatory cytokines
in C3H/HeN mice but not in lipopolysaccharide (LPS)-resistant C3H/HeJ
mice that have a defect in the Toll-like receptor 4 (TLR4) gene, both
in vivo and in vitro, similarly to LPS (T. Monodane, Y. Kawabata, S. Yang, S. Hase, and H. Takada, J. Med. Microbiol. 50:4-12, 2001). In this study, we found that purified TUA (p-TUA) induced tumor necrosis factor alpha (TNF-
) in murine monocytic J774.1 cells but
not in mutant LR-9 cells expressing membrane CD14 at a lower level than
the parent J774.1 cells. The TNF-
-inducing activity of p-TUA in
J774.1 cells was completely inhibited by anti-mouse CD14 monoclonal
antibody (MAb). p-TUA also induced interleukin-8 (IL-8) in human
monocytic THP-1 cells differentiated to macrophage-like cells
expressing CD14. Anti-human CD14 MAb, anti-human TLR4 MAb, and
synthetic lipid A precursor IVA, an LPS antagonist, almost completely inhibited the IL-8-inducing ability of p-TUA, as well as
LPS, in the differentiated THP-1 cells. Reduced p-TUA did not exhibit
any activities in J774.1 or THP-1 cells. These findings strongly
suggested that M. luteus TUA activates murine and human monocytic cells in a CD14- and TLR4-dependent manner, similar to LPS.
 |
INTRODUCTION |
The gram-positive organism
Micrococcus luteus (formerly Micrococcus
lysodeikticus) was initially isolated from the nasal secretion of
a patient with acute coryza (6). Human skin is considered to be a primary habitat of the bacterium, and it has also been detected
in the mucous membranes as well as in water and soil (18).
Recently, this organism was recognized as an opportunistic pathogen and
has been implicated in recurrent bacteremia (29, 44),
septic shock (3), septic arthritis (45),
endocarditis (5, 10, 35), meningitis (7),
intracranial suppuration (36), and cavitating pneumonia in
immunosuppressed patients (38).
We found that M. luteus cells and cell walls induced serum
cytokines in muramyldipeptide-primed mice (24). M. luteus cell walls consist of two polymers, i.e., peptidoglycans
(9, 33) and teichuronic acids (TUA) (14, 26,
30), which are composed of
N-acetyl-D-mannosaminuronic acid and
D-glucose residues covalently bonded to each other (Fig.
1). Unlike the usual peptidoglycans from
various gram-positive bacteria, those from M. luteus lacked immunomodulating activities such as immunoadjuvant activity
(19), antitumor activity (11), mitogenic
activity (12), and cytokine-inducing activity
(21). We showed that the cytokine-inducing activity of
M. luteus cell walls was attributable to the TUA portion and not to the peptidoglycan portion (25). Furthermore, the
activity of TUA was detected in an in vivo experiment using C3H/HeN
mice and in peritoneal macrophage cultures from C3H/HeN mice but not from C3H/HeJ mice (25).
C3H/HeJ mice are genetically resistant to the immunobiological
activities of lipopolysaccharides (LPS) (39). Recent
studies indicated that a missense mutation in the third exon of the
Toll-like receptor 4 (TLR4) gene in C3H/HeJ mice, which replaced
proline with histidine at position 712 of TLR4, rendered the mice
resistant to endotoxin (31, 32). Akira's group (16,
40, 41) then demonstrated that TLR2 was essential for the
responses to peptidoglycans and lipopeptide, while TLR4 was
essential for the responses to lipoteichoic acid as well as to LPS, in
peritoneal macrophage cultures from TLR2 and TLR4 knockout mice.
In the present study, we first examined whether M. luteus
TUA activated murine and human monocytic cells. We then examined the
possible involvement of CD14 and TLR4 in the responses of the cells to
TUA, which are similar to those to LPS.
 |
MATERIALS AND METHODS |
Reagents.
Purified TUA (p-TUA) were prepared from
M. luteus NCTC 2665 as described previously
(14). Briefly, the cell walls from stationary-phase M. luteus cells were digested with egg white lysozyme and
L11 enzyme and then fractionated through an
ECTEOLA-cellulose column. To obtain TUA with aminohexose residues
(p-TUA-[H]) instead of the original aminohexuronic acid residues,
p-TUA was acetylated with acetic anhydride, reduced with diborane, and
treated with mild alkali to remove O-acetyl groups. The
structures of p-TUA and p-TUA-[H] are shown in Fig. 1. The possible
contaminating LPS contents in p-TUA and p-TUA-[H] were calculated as
0.091 and 0.070 ng/mg, respectively, based on the results of the
colorimetric Limulus test using Escherichia coli
O111:B4 LPS as a control (25). Ultrapurified LPS prepared
from Salmonella choleraesuis subsp. choleraesuis
serovar Abortus-equi (Novo-Pyrexal) (8), a gift from C. Galanos (Max Planck Institut für Immunbiologie, Freiburg, Germany), was used as reference LPS. A synthetic lipid A precursor IVA (LA-14-PP or compound 406) was obtained from Daiichi
Chemical Co. (Tokyo, Japan), and an anti-mouse CD14 monoclonal antibody (MAb) (4C1; rat immunoglobulin G2b [IgG2b]) was prepared as described previously (1). The isotype-matched rat IgG2b, anti-human
CD14 MAb MY4, and isotype-matched mouse IgG2b were obtained from
Coulter Co., (Miami, Fla). Anti-human TLR4 MAb HTA125 was prepared as described previously (37). Unless otherwise indicated,
other reagents were purchased from Sigma Chemical Co. (St. Louis, Mo.).
Cell culture.
The murine macrophage-like cell line J774.1
and the LPS-resistant mutant LR-9 (27) were maintained in
Ham's F12 medium (Gibco BRL, Life Technologies, Grand Island, N.Y.)
supplemented with 10% fetal calf serum (FCS) in tissue culture dishes
at 37°C in a humidified 5% CO2 atmosphere. Cells of the
human monocytic leukemia cell line THP-1 were cultured in RPMI 1640 medium with 10% FCS (Flow Laboratories, Inc., McLean, Va.) in tissue
culture dishes (Falcon; Becton Dickinson Labware, Lincoln Park, N.J.)
at 37°C in a humidified 5% CO2 atmosphere. The THP-1
cells were maintained in logarithmic growth phase (2 × 105 to 1 × 106/ml) by passage every 3 to
4 days. Cells (2 × 105/ml) were then treated with 0.1 µM 22-oxyacalcitriol (OCT), an analogue of 1
, 25-dihydroxy-vitamin
D3 (Chugai Pharmaceutical Co., Tokyo, Japan)
(20), for 3 days. OCT treatment induced differentiation of
THP-1 cells to macrophage-like cells strongly expressing membrane CD14
(mCD14) (45a).
Flow cytometry.
The confluent J774.1 and LPS-resistant
mutant LR-9 cells were analyzed for expression of mCD14 by flow
cytometry. The cells were collected and washed once with
phosphate-buffered saline. The cells were then stained with fluorescein
isothiocyanate-conjugated anti-mouse CD14 MAb (rmC5-3) (PharMingen, San
Diego, Calif.) at 4°C for 30 min. Flow cytometric analyses were
performed with a fluorescence-activated cell sorter (FACScan; Becton Dickinson).
Cytokine assay.
The confluent J774.1, LR-9, and
OCT-treated THP-1 cells were collected and washed twice with
phosphate-buffered saline. The J774.1 and LR-9 cells
(105/200 µl per well) were incubated in Ham's F12 medium
with 1% FCS, and the THP-1 cells (105/200 µl per well)
were incubated in RPMI 1640 medium with 1% FCS, with or without
stimulants for 24 h. In antibody blocking and antagonist-inhibitory experiments, cells were preincubated with MAbs or
inhibitor (LA-14-PP) for 30 min and then incubated with stimulants.
After incubation, the cytokine levels in the culture supernatants were
determined using enzyme-linked immunosorbent assay (ELISA) kits
(Pharmingen). Tumor necrosis factor alpha (TNF-
) production by
J774.1 and LR-9 cells and interleukin-8 (IL-8) production by
OCT-treated THP-1 cells were measured. The concentrations of cytokines
in the supernatants were determined using the Softmax data analysis
program (Molecular Devices Corp., Menlo Park, Calif.). Each assay was
carried out in triplicate.
Statistical analysis.
All experiments were performed at
least three times. The data shown are representative results and are
means ± standard deviations. The statistical significance of
differences between each test group and its respective control was
examined by Student's t test.
 |
RESULTS |
Expression of mCD14 by J774.1 and LR-9 cells in culture.
LR-9
cells were originally isolated from J774.1 cells as an LPS-resistant
mutant with a defect in LPS binding (13) and later were
reported to lack mCD14 (27). Therefore, we first compared mCD14 expression by J774.1 cells with that by LR-9 cells by flow cytometry. The J774.1 cells were clearly stained with anti-mouse CD14
MAb, whereas LR-9 cells were only weakly stained (Fig.
2). These results indicated that the
parent J774.1 and the mutant LR-9 cells express mCD14 at high and low
levels, respectively.

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 2.
mCD14 expression in J774.1 and LR-9 cells in culture.
J774.1 (A) and LR-9 (B) cells were stained with fluorescein
isothiocyanate-labeled anti-mouse CD14 MAb (rmC5-3) and analyzed by
fluorescence-activated cell sorter analysis. The results shown are
representative of those from three different experiments.
|
|
Induction of TNF-
production by p-TUA in J774.1 and LR-9
cells in culture.
First, we examined the potency of p-TUA to
induce TNF-
production in J774.1 and LR-9 cells in culture. In
J774.1 cells, p-TUA exhibited a definite activity to induce TNF-
release in a concentration-dependent manner from 1 to 100 µg/ml (Fig.
3A). In the same experiment, the
reference LPS induced TNF-
production in a concentration-dependent manner from 1 to 100 ng/ml and exhibited a plateau response at 100 ng/ml to 10 µg/ml. In accordance with a previous report by Nishijima
et al. (27), LR-9 cells did not respond to the lower concentrations of LPS (1 to 100 ng/ml) and showed only a slight response to the higher concentrations (1 and 10 µg/ml) (Fig. 3B). In
LR-9 cell cultures, p-TUA showed almost no ability to induce TNF-
;
no activity was seen 1 ng/ml to 50 µg/ml, and slight but negligible
activity was observed at 100 µg/ml. In contrast, both J774.1 and LR-9
cells responded to a CD14-independent stimulant, phorbol myristate
acetate, to similar extents (Fig. 4).
These findings strongly suggested that p-TUA activates J774.1 cells preferentially in an mCD14-dependent manner.

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 3.
Induction of TNF- by p-TUA in J774.1 and LR-9 cells.
J774.1 (A) and LR-9 (B) cells were stimulated with p-TUA and reference
Salmonella serovar Abortus-equi LPS at the indicated
concentrations for 24 h in triplicate. The TNF- levels in the
culture supernatants were determinated by ELISA, and are expressed as
means ± standard deviations. *, P < 0.05;
**, P < 0.01 (versus medium alone). The results
are representative of those from three different experiments.
|
|

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 4.
Induction of TNF- by PMA in J774.1 and LR-9 cells.
J774.1 (A) and LR-9 (B) cells were stimulated with phorbol myristate
acetate (PMA) and reference Salmonella serovar Abortus-equi
LPS at the indicated concentrations for 24 h in triplicate. The TNF-
levels in the culture supernatants were determinated by ELISA and are
expressed as means ± standard deviations. **, P < 0.01 versus medium alone. The results are representative of those
from two different experiments.
|
|
Blocking effect of anti-mouse CD14 MAb on TNF-
secretion
by J774.1 cells in response to p-TUA.
To further determine whether
p-TUA activated J774.1 cells in an mCD14-dependent manner, J774.1 cells
were preincubated with anti-mouse CD14 MAb 4C1 (50 µg/ml) for 30 min
and then stimulated with p-TUA (50 µg/ml) or reference LPS (10 ng/ml)
for 24 h. Pretreatment of J774.1 cells with the anti-mouse CD14
MAb almost completely inhibited the p-TUA-induced TNF-
release (Fig.
5). In accordance with the results shown
in Fig. 3, the blocking effect of the MAb on TNF-
release induced by
p-TUA was observed more clearly than that induced by the reference LPS.
These findings shown in Fig. 3 to 5 clearly indicate that p-TUA
activated J774.1 cells preferentially in an mCD14-dependent manner.

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 5.
Blocking effect of anti-mouse CD14 MAb on TNF-
secretion by J774.1 cells in response to p-TUA. J774.1 cells were
preincubated with anti-mouse CD14 MAb 4C1 or isotype-matched control
antibody (50 µg/ml) for 30 min and then stimulated with p- TUA (50 µg/ml) and reference LPS (10 ng/ml) for 24 h. The levels of
TNF- in the culture supernatants were determined by ELISA and are
expressed as means ± standard deviations for triplicate cultures.
**, P < 0.01 versus the respective control. The
results are representative of those from four different experiments.
|
|
Induction of IL-8 secretion by p-TUA in THP-1 cells in
culture.
We further examined the cytokine-inducing activity of
p-TUA in OCT-differentiated human monocytic THP-1 cells. p-TUA induced IL-8 in a concentration-dependent manner from 1 to 100 µg/ml in the
THP-1 cells. The maximum IL-8 level induced by p-TUA (100 µg/ml) was
comparable to that induced by reference LPS (0.01 to 10 µg/ml),
although considerably higher concentrations of p-TUA were required to
exert sufficient activity compared with LPS (Fig. 6).

View larger version (54K):
[in this window]
[in a new window]
|
FIG. 6.
Induction of IL-8 release by p-TUA in THP-1 cells in
culture. The OCT-differentiated THP-1 cells were stimulated by p-TUA
and reference Salmonella serovar Abortus-equi LPS at the
indicated concentrations for 24 h in triplicate. The IL-8 levels
in THP-1 cell culture supernatants were determined by ELISA and are
expressed as means ± standard deviations. **, P < 0.01 versus medium alone. The results are representative of those
from three different experiments.
|
|
Blocking effect of anti-human CD14 MAb on IL-8 secretion by
THP-1 cells in response to p-TUA.
To determine whether p-TUA also
activated THP-1 cells in a CD14-dependent manner, OCT-differentiated
THP-1 cells were preincubated with anti-human CD14 MAb MY4 (10 µg/ml)
or isotype-matched antibody (IgG2b) for 30 min and then stimulated with
p-TUA (50 µg/ml) or reference LPS (10 ng/ml). Pretreatment of the
THP-1 cells with anti-human CD14 MAb inhibited IL-8 production induced
by p-TUA to almost the same level as observed with medium alone (Fig.
7). This result suggested that p-TUA
activated OCT-differentiated THP-1 cells in a CD14 (probably
mCD14)-dependent manner similarly to LPS.

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 7.
Blocking effect of anti-human CD14 MAb on IL-8 secretion
by THP-1 cells in response to p-TUA. The OCT-differentiated THP-1 cells
were preincubated with anti-human CD14 MAb MY4 or isotype-matched
control antibody (10 µg/ml) for 30 min and then stimulated with p-TUA
(50 µg/ml) or reference LPS (10 ng/ml) for 24 h in triplicate.
The IL-8 levels in the culture supernatants were determined by ELISA
and are expressed as means ± standard deviations. **,
P < 0.01 versus the respective control. The results
are representative of those from three different experiments.
|
|
Blocking effect of anti-TLR4 MAb on IL-8 secretion by THP-1 cells
in response to p-TUA.
Next, we examined whether TLR4 is involved
in IL-8 production by THP-1 cells in response to p-TUA similarly to
LPS. OCT-treated THP-1 cells were preincubated with anti-human TLR4 MAb
HTA125 (5 µg/ml) or isotype-matched antibody IgG2a for 30 min and
then stimulated with p-TUA (50 µg/ml) or reference LPS (10 ng/ml). The IL-8 release induced by p-TUA was markedly inhibited by HTA125 to
an extent similar to that for LPS (Fig.
8). This result suggested that p-TUA
activated THP-1 cells in the same (i.e., TLR4-dependent) manner as LPS.

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 8.
Blocking effect of anti-human TLR4 MAb on IL-8 secretion
by THP-1 cells in response to p-TUA. The OCT-differentiated THP-1 cells
were preincubated with anti-human TLR4 MAb HTA125 or isotype-matched
control antibody (5 µg/ml) for 30 min and then stimulated with p-TUA
(50 µg/ml) or reference LPS (10 ng/ml) for 24 h in triplicate.
The IL-8 levels in the culture supernatants were determined by ELISA
and are expressed as means ± standard deviations. **,
P < 0.01 versus the respective control. The results
are representative of those from three different experiments.
|
|
Inhibitory effect of LA-14-PP on IL-8 secretion by THP-1 cells in
response to p-TUA.
LA-14-PP is an endotoxin antagonist in human
cells and has been suggested to antagonize LPS at multiple sites in the
LPS recognition pathway (17, 22). Therefore, we examined
the possible antagonistic effects of LA-14-PP against p-TUA in
OCT-differentiated THP-1 cells. The IL-8 release induced by p-TUA was
markedly inhibited by LA-14-PP in a concentration-dependent manner
(Fig. 9). Complete inhibition was
observed at 10 µg of LA-14-PP per ml versus 50 µg of p-TUA per ml
and at 1 µg LA-14-PP versus 10 ng of LPS per ml.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 9.
Inhibitory effect of LA-14-PP on IL-8 secretion by
THP-1 cells in response to p-TUA. The OCT-differentiated THP-1 cells
were preincubated with 1 or 10 µg of LA-14-PP per ml for 30 min and
then stimulated with p-TUA (50 µg/ml) or reference LPS (10 ng/ml) for
24 h in triplicate. The IL-8 levels in the culture supernatants
were determined by ELISA and are expressed as means ± standard
deviations. **, P < 0.01 versus the respective
control. The results are representative of those from three different
experiments.
|
|
Inactivity of p-TUA-[H] in both J774.1 and THP-1
cells.
The above findings suggested that the receptor system is
shared by p-TUA and LPS, i.e., is mCD14 and TLR4 dependent. As
mentioned in Materials and Methods, the Limulus test
suggested that the p-TUA preparations might have been slightly
contaminated with LPS (0.091 ng/mg). To exclude the possibility that
the activities of p-TUA were due to contaminating LPS in the
preparation, the activity of the reduced p-TUA (p-TUA-[H]) compared
with that of the parent p-TUA was examined in J774.1 and OCT-treated
THP-1 cells in culture, because the activity of p-TUA-[H] might be
similarly affected by contamination with LPS (0.070 ng/mg). In contrast to p-TUA, p-TUA-[H] was completely devoid of cytokine-inducing activity in J774.1 (Fig. 10A) and THP-1
(Fig. 10B) cells in culture. These results support the conclusion that
the activities of p-TUA were inherent and not attributable to
contaminating LPS in the p-TUA preparations.

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 10.
Inability of p-TUA-[H] to induce cytokines in
J774.1 and THP-1 cells in culture. J774.1 (A) and the
OCT-differentiated THP-1 (B) cells were stimulated with p-TUA,
p-TUA-[H], and reference LPS at the indicated concentrations for
24 h in triplicate. The TNF- and IL-8 levels in the culture
supernatants of J774.1 and THP-1 cells, respectively, were determinated
by ELISA and are expressed as means ± standard deviations.
**, P < 0.01; *, P < 0.05
(versus medium alone). The results are representative of those from
three different experiments.
|
|
 |
DISCUSSION |
In this study, we demonstrated that the cell wall TUA from
the gram-positive organism M. luteus activated human
monocytic THP-1 cells in a CD14- and TLR4-dependent manner and that the TUA also activated murine monocytic J774.1 cells in a CD14-dependent manner. CD14 is known to be a pattern recognition molecule and to
recognize common structures on various bacterial cell surfaces (43). The TUA is a special structure of the M. luteus cell wall, and therefore this finding is clear evidence
that this special structure is also recognized by CD14. TLR4 is
involved mainly in recognition of gram-negative bacteria, probably
through recognition of the LPS portion, while TLR2 is involved mainly
in recognition of gram-positive bacteria, probably through recognition
of the peptidoglycan portion (2, 23, 42). However, this is
not necessarily the case, because (i) peptidoglycans, which are
recognized by TLR2 (34, 40, 46), are distributed
ubiquitously in both gram-positive and gram-negative bacteria, although
their contents in the cell wall are high and low, respectively; (ii)
another ubiquitous component, lipoprotein (or lipopeptide), which
frequently coexists with LPS as endotoxin protein, is recognized by
TLR2 (15, 41); and (iii) lipoteichoic acid, which is
widely distributed in gram-positive bacteria, is recognized by TLR4
(40), although the converse result was also reported
(34). This is the first report of a TLR4-recognized
chemically defined cell surface component prepared from gram-positive
bacteria. Furthermore, immunobiological activities of this bacterium
are attributable mainly to TUA (25), because
peptidoglycans of this bacterium lacked bioactivities, as described
above. Thus, it is possible that whole cells of this gram-positive
bacterium might be recognized by TLR4, not by TLR2, unlike the case for
most gram-positive bacteria. Further experiments to investigate this
possibility using various micrococcal cells and cell walls are in progress.
The possible unique recognition system for M. luteus
might be of some advantage for the bacterium to colonize tissues by
escaping from the innate immune system of the host. Hosts carrying TLR4 mutations (4) might be sensitive to infection by M. luteus as well as gram-negative bacteria. Furthermore, hosts in a
state of endotoxin tolerance, where function of TLR4 is down-regulated (28), probably to avoid harmful effects of endotoxic
activity, would be easily infected with M. luteus.
This work was supported in part by Grants-in-Aid for Scientific
Research (no. 10470378, 11671796, and 12470380) from the Ministry of
Education, Culture, Sports, Science, and Technology of Japan.
| 1.
|
Adachi, Y.,
C. Satokawa,
M. Saeki,
N. Ohno,
H. Tamura,
S. Tanaka, and T. Yadomae.
1999.
Inhibition by a CD14 monoclonal antibody of lipopolysaccharide binding to murine macrophages.
J. Endotoxin Res.
5:139-146.
|
| 2.
|
Aderem, A., and R. J. Ulevitch.
2000.
Toll-like receptors in the induction of the innate immune response.
Nature
406:782-787[CrossRef][Medline].
|
| 3.
|
Albertson, D.,
G. A. Natsios, and R. Gleckman.
1978.
Septic shock with Micrococcus luteus.
Arch. Intern. Med.
138:487-488[Abstract].
|
| 4.
|
Arbour, N. C.,
E. Lorenz,
B. C. Schutte,
J. Zabner,
J. N. Kline,
M. Jones,
K. Frees,
J. L. Watt, and D. A. Schwartz.
2000.
TLR4 mutations are associated with endotoxin hyporesponsiveness in humans.
Nat. Genet.
25:187-191[CrossRef][Medline].
|
| 5.
|
Dürst, U. N.,
E. Bruder,
L. Egloff,
J. Wust,
J. Schneider, and H. O. Hirzel.
1991.
Micrococcus luteus: Ein seltener Erreger einer Klappenprothesenendokarditis.
Z. Kardiol.
80:294-298[Medline].
|
| 6.
|
Fleming, A.
1922.
On a remarkable bacteriolytic element found in tissues and secretions.
Proc. R. Soc. B
93:306-317.
|
| 7.
|
Fosse, T.,
Y. Peloux,
C. Granthil,
B. Toga,
J. Bertrando, and M. Sethian.
1985.
Meningitis due to Micrococcus luteus.
Infection
13:280-281[CrossRef][Medline].
|
| 8.
|
Galanos, C.,
O. Lüderitz, and O. Westphal.
1979.
Preparation and properties of a standardized lipopolysaccharide from Salmonella abortus equi (Novo-Pyrexal).
Zentbl. Bakteriol. Hyg. Abt. 1
243:226-244.
|
| 9.
|
Ghuysen, J.-M.,
E. Bricas,
M. Lache, and M. Leyh-Bouille.
1968.
Structure of the cell walls of Micrococcus lysodeikticus. III. Isolation of a new peptide dimer, N -[L-alanyl- -( -D-glutamyl-glycine)]-L-lysyl-D-alanyl-N -[L-alanyl-( -D-glutamyl-glycine)]-L-lysyl-D-alanine.
Biochemistry
7:1450-1460[CrossRef][Medline].
|
| 10.
|
Glupezynski, Y.,
H. Lagast,
P. Van der Auwera,
J. P. Thys,
F. Crokaert,
E. Yourassowsky,
F. Meunier-Carpentier,
J. Klastersky,
J. P. Kanins,
E. Serruys-Schoutens, and J. C. Legrand.
1986.
Clinical evaluation of teicoplanin for therapy of severe infections caused by gram-positive bacteria.
Antimicrob. Agents Chemother.
29:52-57[Abstract/Free Full Text].
|
| 11.
|
Goguel, A.-F.,
G. Lespinats, and C. Nauciel.
1982.
Peptidoglycans extracted from gram-positive bacteria: expression of antitumor activity according to peptide structure and route of injection.
JNCI
68:657-663.
|
| 12.
|
Guenounou, M.,
A.-F. Goguel, and C. Nauciel.
1982.
Study of adjuvant and mitogenic activities of bacterial peptidoglycans with different structures.
Ann. Immunol. (Paris)
133:3-13.
|
| 13.
|
Hara-Kuge, S.,
F. Amano,
M. Nishijima, and Y. Akamatsu.
1990.
Isolation of a lipopolysaccharide (LPS)-resistant mutant, with defective LPS binding, of cultured macrophage-like cells.
J. Biol. Chem.
265:6606-6610[Abstract/Free Full Text].
|
| 14.
|
Hase, S., and Y. Matsushima.
1972.
Structural studies on a glucose-containing polysaccharide obtained from cell walls of Micrococcus lysodeikticus. III. Determination of the structure.
J. Biochem. (Tokyo)
72:1117-1128[Abstract/Free Full Text].
|
| 15.
|
Hirschfeld, M.,
Y. Ma,
J. H. Weis,
S. N. Vogel, and J. J. Weis.
2000.
Repurification of lipopolysaccharide eliminates signaling through both human and murine Toll-like receptor 2.
J. Immunol.
165:618-622[Abstract/Free Full Text].
|
| 16.
|
Hoshino, K.,
O. Takeuchi,
T. Kawai,
H. Sanjo,
T. Ogawa,
Y. Takeda,
K. Takeda, and S. Akira.
1999.
Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product.
J. Immunol.
162:3749-3752[Abstract/Free Full Text].
|
| 17.
|
Kitchens, R. L., and R. S. Munford.
1995.
Enzymatically deacylated lipopolysaccharide (LPS) can antagonize LPS at multiple sites in the LPS recognition pathway.
J. Biol. Chem.
270:9904-9910[Abstract/Free Full Text].
|
| 18.
|
Kocur, M.,
W. E. Kloos, and K.-H. Schleifer.
1992.
The genus Micrococcus, p. 1300-1311.
In
A. Balows, H. G. Truper, M. Dworkin, W. Harder, and K.-H. Schleifer (ed.), The prokaryotes, 2nd ed., vol. II. Springer Verlag, New York, N.Y.
|
| 19.
|
Kotani, S.,
T. Narita,
D. E. S. Stewart-Tull,
T. Shimono,
Y. Watanabe,
K. Kato, and S. Iwata.
1975.
Immunoadjuvant activities of cell walls and their water-soluble fractions prepared from various gram-positive bacteria.
Biken J.
18:77-92[Medline].
|
| 20.
|
Kubodera, N.,
K. Sato, and Y. Nishii.
1997.
Characteristics of 22-oxacalcitriol (OCT) and 2 -(3-hydroxypropoxy)-calcitriol (ED-71), p. 1071-1086.
In
D. Feldman, F. H. Glorieux, and J. W. Pike (ed.), Vitamin D. Academic Press, San Diego, Calif.
|
| 21.
|
Lawrence, C., and C. Nauciel.
1998.
Production of interleukin-12 by murine macrophages in response to bacterial peptidoglycan.
Infect. Immun.
66:4947-4949[Abstract/Free Full Text].
|
| 22.
|
Lynn, W. A., and D. T. Golenbock.
1992.
Lipopolysaccharide antagonists.
Immunol. Today
13:271-276[CrossRef][Medline].
|
| 23.
|
Means, T. K.,
D. T. Golenbock, and M. J. Fenton.
2000.
The biology of Toll-like receptors.
Cytokine Growth Factor Rev.
11:219-232[CrossRef][Medline].
|
| 24.
|
Monodane, T.,
Y. Kawabata, and H. Takada.
1997.
Micrococcus luteus cells and cell walls induce anaphylactoid reactions accompanied by early death and serum cytokines in mice primed with muramyl dipeptide.
FEMS Immunol. Med. Microbiol.
17:49-55[CrossRef][Medline].
|
| 25.
|
Monodane, T.,
Y. Kawabata,
S. Yang,
S. Hase, and H. Takada.
2001.
Induction of tumour necrosis factor- and interleukin-6 in mice in vivo and in murine peritoneal macrophages and human whole blood cells in vitro by Micrococcus luteus teichuronic acids.
J. Med. Microbiol.
50:4-12[Abstract/Free Full Text].
|
| 26.
|
Nasir-ud-Din, R. W., and Jeanloz.
1976.
The chemical structure of a fragment of Micrococcus lysodeikticus cell-wall.
Carbohydr. Res.
47:245-260[CrossRef][Medline].
|
| 27.
|
Nishijima, M.,
S. Hara-Kuge,
N. Takasuka,
K. Akagawa,
M. Setouchi,
K. Matsuura,
S. Yamamoto, and Y. Akamatsu.
1994.
Identification of a biochemical lesion, and characteristic response to lipopolysaccharide (LPS) of a cultured macrophage-like cell mutant with defective LPS-binding.
J. Biochem. (Tokyo)
116:1082-1087[Abstract/Free Full Text].
|
| 28.
|
Nomura, F.,
S. Akashi,
Y. Sakao,
S. Sato,
T. Kawai,
M. Matsumoto,
K. Nakanishi,
M. Matsumoto,
K. Nakanishi,
M. Kimoto,
K. Miyake,
K. Takeda, and S. Akira.
2000.
Endotoxin tolerance in mouse peritoneal macrophages correlates with down-regulation of surface Toll-like receptor 4 expression.
J. Immunol.
164:3476-3479[Abstract/Free Full Text].
|
| 29.
|
Peces, R.,
E. Gago,
F. Tejada,
A. S. Laures, and J. Alvarez-Grande.
1997.
Relapsing bacteremia due to Micrococcus luteus in a haemodialysis patient with a Perm-Cath catheter.
Nephrol. Dial. Transplant.
12:2428-2429[Abstract/Free Full Text].
|
| 30.
|
Perkins, H. R.
1963.
A polymer containing glucose and aminohexuronic acid isolated from the cell walls of Micrococcus lysodeikticus.
Biochem. J.
86:475-483[Medline].
|
| 31.
|
Poltorak, A.,
X. He,
I. Smirnova,
M.-Y. Liu,
C. Van Huffel,
X. Du,
D. Birdwell,
E. Alejos,
M. Silva,
C. Galanos,
M. Freudenberg,
P. Ricciardi-Castagnoli,
B. Layton, and B. Beutler.
1998.
Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene.
Science
282:2085-2088[Abstract/Free Full Text].
|
| 32.
|
Qureshi, S. T.,
L. Larivière,
G. Leveque,
S. Clermont,
K. J. Moore,
P. Gros, and D. Malo.
1999.
Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4).
J. Exp. Med.
189:615-625[Abstract/Free Full Text].
|
| 33.
|
Schleifer, K. H., and O. Kandler.
1967.
Micrococcus lysodeikticus: a new type of cross-linkage of murein.
Biochem. Biophys. Res. Commun.
28:965-972[CrossRef][Medline].
|
| 34.
|
Schwandner, R.,
R. Dziarski,
H. Wesche,
M. Rothe, and C. J. Kirschning.
1999.
Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by Toll-like receptor 2.
J. Biol. Chem.
274:17406-17409[Abstract/Free Full Text].
|
| 35.
|
Seifert, H.,
M. Kaltheuner, and F. Perdreau-Remington.
1995.
Micrococcus luteus endocarditis: case report and review of the literature.
Int. J. Med. Microbiol.
282:431-435.
|
| 36.
|
Selladurai, B. M.,
S. Sivakumaran,
S. Aiyar, and A. R. Mohamad.
1993.
Intracranial suppuration caused by Micrococcus luteus.
Br. J. Neurosurg.
7:205-208[Medline].
|
| 37.
|
Shimazu, R.,
S. Akashi,
H. Ogata,
Y. Nagai,
K. Fukudome,
K. Miyake, and M. Kimoto.
1999.
MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4.
J. Exp. Med.
189:1777-1782[Abstract/Free Full Text].
|
| 38.
|
Souhami, L.,
R. Feld,
P. G. Tuffnell, and T. Feller.
1979.
Micrococcus luteus pneumonia: a case report and review of the literature.
Med. Pediatr. Oncol.
7:309-314[Medline].
|
| 39.
|
Sultzer, B. M.
1968.
Genetic control of leucocyte responses to endotoxin.
Nature
219:1253-1254[CrossRef][Medline].
|
| 40.
|
Takeuchi, O.,
K. Hoshino,
T. Kawai,
H. Sanjo,
H. Takada,
T. Ogawa,
K. Takeda, and S. Akira.
1999.
Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components.
Immunity
11:443-451[CrossRef][Medline].
|
| 41.
|
Takeuchi, O.,
A. Kaufmann,
K. Grote,
T. Kawai,
K. Hoshino,
M. Morr,
P. F. Mühlradt, and S. Akira.
2000.
Preferentially the S-stereoisomer of the mycoplasmal lipopeptide macrophage-activating lipopeptide-2 activates immune cells through a Toll-like receptor 2- and MyD88-dependent signaling pathway.
J. Immunol.
164:554-557[Abstract/Free Full Text].
|
| 42.
|
Ulevitch, R. J.
1999.
Toll gates for pathogen selection.
Nature
401:755-756[Medline].
|
| 43.
|
Ulevitch, R. J., and P. S. Tobias.
1995.
Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin.
Annu. Rev. Immunol.
13:437-457[CrossRef][Medline].
|
| 44.
|
Von Eiff, C.,
N. Kuhn,
M. Herrmann,
S. Weber, and G. Peters.
1996.
Micrococcus luteus as a cause of recurrent bacteremia.
Pediatr. Infect. Dis. J.
15:711-713[CrossRef][Medline].
|
| 45.
|
Wharton, M.,
J. R. Rice,
R. McCallum, and H. A. Gallis.
1986.
Septic arthritis due to Micrococcus luteus.
J. Rheumatol.
13:659-660[Medline].
|
| 45a.
|
Yang, S.,
R. Tamai,
S. Akashi,
O. Takeuchi,
S. Akira,
S. Sugawara, and H. Takada.
2001.
Synergistic effect of muramyldipeptide with lipopolysaccharide or lipoteichoic acid to induce inflammatory cytokines in human monocytic cells in culture.
Infect. Immun.
69:2045-2053[Abstract/Free Full Text].
|
| 46.
|
Yoshimura, A.,
E. Lien,
R. R. Ingalls,
E. Tuomanen,
R. Dziarski, and D. Golenbock.
1999.
Recognition of gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2.
J. Immunol.
163:1-5[Abstract/Free Full Text].
|